12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Actelion sales and marketing update

Actelion launched Opsumit macitentan in the U.S. to treat pulmonary arterial hypertension (PAH)....

Read the full 55 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >